5:20 PM
 | 
Mar 05, 2007
 |  BC Extra  |  Top Story

InterMune dropping Actimmune for IPF

ITMN will discontinue development of Actimmune for idiopathic pulmonary fibrosis after a planned interim analysis in the Phase III INSPIRE trial showed the interferon (IFN) gamma-1b did not significantly improve overall survival vs. placebo. As...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >